Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Conditions

Hepatorenal Syndrome

What is the purpose of this trial?

Cumberland Pharmaceuticals Inc. (CPI) is developing ifetroban for treatment of hepatorenal syndrome (HRS) and proposes to conduct a study in hospitalized adult patients with HRS to assess the safety and pharmacokinetics of escalating doses of ifetroban.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Cumberland Pharmaceuticals
Dates:
October 2011
Last Updated:
January 25, 2013
Study HIC#:
1106008595

Clinicaltrials.gov ID: NCT01436500